Complete metabolic response was observed in 5 (27.8%) cHL anti‐PD‐1/PD‐L1 naïve patients, 2 (16.7%) cHL anti‐PD‐1/PD‐L1 progressors, and 1 (5.9%) DLBCL patient. Here, CD274 is linked to diffuse large B-cell lymphoma.